Merck KGAA’s Big Second Bet On Cancer
Andree Blaukat, Merck KGAA's SVP and head of the Translational Innovation Platform Oncology, discusses the company's DNA repair pipeline.
You may also be interested in...
Insights from Gates Medical Research Institute CEO Dr. Penny Heaton.
In Vivo visits Gates Medical Research Institute CEO Dr. Penny Heaton to review its first pipeline of drugs and vaccines to attack four of the world’s biggest killers: TB, malaria, enteric diseases and other conditions affecting maternal, newborn and child health.
Big pharma is facing a difficult US competitive landscape as its traditional customers realign to build their own redoubts of size, scale and reach.